Introduction
Increased amounts of neopterin are released from hum a n ma crop hages o n stimulation with interferon gamma. Thu s. neopterin is a va luable marker of cellular immune activation (1. 2). From in vitro st udies th ere is evide nce that cytokines such as interfero n gamma and tumour nec rosis factor alpha. which are released from activated immune cells. are capable to in hibit haemato poiesis (3. 4) . In patients with m a li gnant disease (5 . 6) and with chronic infec tion s (7) we found a significant nega tive correlatio n between neopterin a nd h ae moglobin concentrations. More detail ed examinations of iron status in patients with gynaecological neoplasias revealed a significant negative correlation between ncopterin a nd serum iron concentrations (8) .
With these d ata in mind , we were interested to see k for a dircct interactio n betwecn formation of neopterin and neopterin derivatives from macrophages and the altered iron mctaboli sm . Increased neopterin concentrations in pati en ts and in supernatants of acti vated macrophages a re accompanied by a n increase of 7,8-dihydro neopte rin (9. 10). The latter compo und is a potent reducing agent.
In this stud y we investiga ted the chemical possibility to reduce F e' j with 7.S-dihydroneopterin .
Methods
As a sta ndard protocol to assess the reduction of iron. we reduced ferric iron F e"' I by va riou s co ncentratio ns of ascorbic acid at different pH-values. We used " To w ho m correspondcnce sho ul d be a ddressed. I . which is soluble in wa ter. The complex was quantitated by meas urem ent of UV -VIS absorption at a wavelength of 562 nm (Shimadzu UV 100-1 . Kyoto, Japa n).
The stand ard a ssay to reduce F e' j by ascorbic acid a nd subsequent m eas urem ent of Fe1+ -Ferrozine complex was reproducible in a pH-range from 5.5 to 7.2. The limi t of detectio n was 3 f..lmol / L Fe 2 I • The calibration curve was linear within a concentration ran ge of Fe' I between 0-200 f..lmol fL.
The reductive capacity of 7,8-dihydro neopterin was tested wi th Fe'+ salts under ana logous conditions and compared to the reactivity of ascorbic acid . The effect of reagent concentrations and of pH-value was investigated .
Results
7,8-Dihydroneopterin was ca pable of reducing Fe" I ( Fig. 1) . Reduction of Fe' -was detec ta ble at concentrations of 7.8-dih ydroneopterin below 1.0 f..lmol / L a nd reached a pl a teau at concentrations above 10 f. . l 11101 ; L.
T he effective concentrations of dih ydro neopterin and of ascorbic acid were within a comparable ra nge. At lower concentrations 7,8-dihydroneopterin was even m ore effective (Fig. 1) . The reduction of Fe" by ascorbic acid was not or only marginally influenced by changes of pH. The reduction by 7Js-dih ydroneopterin decreases at higher pH but the effect was moderate, and the reaction was still occurring at physiological pH (Fig. 2) .
During pilot studies, we observed an inhibitory effect of phosphate on reduction of Fe' I . This effect is more pronounced with 7.8-dihydroneopterin than with ascorbic acid. IL is not caused by reaction of phosphate with the ferrozine reagent.
Discussion
Our data clearly demonstrate that 7,8-dihydroneopterin is able to reduce Fe" in aqueous systems. The reductive capacity of 7,8-dihydroneopterin is similar to that of ascorbic acid . Five flmol / L 7.8-dihydroneopterin completely reduced Fe 1 + at physiological pH. Of healthy adult controls. 95 %, have serum neopterin concentrations below 8.7 nmol/ L (1). In patients with infectious diseases, serum neopterin levels were seen to increase sometimes more than 30-fold. Neopterin concentrations may reach levels greater than 100 nmol / L (1, 2). In dialysis patients. levels above 400 nmol / L were observed (11) . The concentrations of 7,8-dih ydroneopterin are on average 3 times higher than the neopterin levels (9). Thus, serum concentrations of 7.8-dihydroneopterin may sometimes reach levels above 1.0 ~lmol / L. At local sites of inflammation the concentrations of 7,8-dihydroneopterin released by activated macrophages may be even higher. reaching levels. which arc within the plateau of the reductive capacity of 7,8-dihydroneopterin (Fig. 1) .
Chronic inflammatory diseases such as chronic infections. autoimmune diseases, and malignant tumors are often associated with hypoferremia (12) . Interestingly. such patients usually do not suffer from reduced dietary intake of iron. They often present with increased ferritin levels (13) , indicating that iron is actively transported from the circulation into storage sites during chronic inflammatory processes. Activation of macrophages by specific cytokines such as interferon gamma and tumour necrosis factor alpha arc very likely to be involved into the depletion of iron in the circulation . Tumor necrosis factor alpha was shown to induce ferritin release and uptake of iron by murine macrophages (14) . Also an influence of activated T -cells on the production of ferritin has been suggested (15) .
In serum , iron is present in its ferric form. Thus, Fe' I has to be reduced, because apoferritin docs only take up Fe 2 1 (16), which then is reoxidized to Fe" (17. 18). The necessary reducing agent is still unknown.
According to our data it appea rs possible that act ivated macrophages release 7,8-dihydroneopterin fo r that reason . No other function of the molecule is known so far. Ce rtainly. o ther potent reducing age nts such as ascorbic acid . glutathi o ne or cysteine could be of relevance. Also other reduced deri vatives of pteridines such as 5,6.7,8- tetra hyd robiopterin are equally able to reduce Fe" . However. activated macroph agcs producc 7,8-dihydroneopterin in excess (9. 10). It remain s to be shown whether 7,8-dih ydroneopteri n, as one of the reductive agents during host defen se of the cellular immune sys tem. could function to withhold iro n from in vading pathogen s (11) . Under the assumption that this speculation is true, then anaemia in chronic infla mmatory disord ers mi ght be a conseq uence of incrcased cytok ine production 1111-tiating transfer of scrum iron into storage si tes .
